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Parkin Suppresses Dopaminergic Neuron-Selective
Neurotoxicity Induced by Pael-R in Drosophila
in PD. This suggests that familial -Syn mutations may
cause PD through a dominant gain-of-function mecha-
nism (Abeliovich et al., 2000). Significantly, wild-type
Yufeng Yang,1 Isao Nishimura,1 Yuzuru Imai,2
Ryosuke Takahashi,2 and Bingwei Lu1,*
1Laboratory of Developmental Neurobiology
-Syn protein was found to be a major component ofRockefeller University
Lewy bodies, the proteinaceous aggregates found in PD1230 York Avenue
and other diseases termed “Synucleinopathies” (Spill-New York, New York 10021
antini et al., 1997; Baba et al., 1998). This suggests that2 Lab for Motor System Neurodegeneration
the accumulation and aggregation of -Syn is intimatelyRIKEN Brain Science Institute
involved in disease pathogenesis. Further support cameSaitama 351-0198
from transgenic animal studies in which overexpressionJapan
of wild-type and mutant forms of -Syn in mouse and
Drosophila led to -Syn aggregate formation and neu-
ronal dysfunction (Feany and Bender, 2000; Masliah etSummary
al., 2000; Giasson et al., 2002; Lee et al., 2002).
Mutations in the parkin gene have been linked to AR-Parkin, an E3 ubiquitin ligase that degrades proteins
JP (Kitada et al., 1998). AR-JP patients develop the typi-with aberrant conformations, is associated with au-
cal parkinsonian symptoms also as a result of loss oftosomal recessive juvenile Parkinsonism (AR-JP). The
midbrain DA neurons. This usually occurs in the absencemolecular basis of selective neuronal death in AR-JP
of Lewy body formation (Mizuno et al., 1998). Biochemi-is unknown. Here we show in an organismal system
cal studies have shown that Parkin has E3 ubiquitin-that panneuronal expression of Parkin substrate
protein ligase activity and that AR-JP-linked parkin mu-Pael-R causes age-dependent selective degeneration
tations abolished this activity (Imai et al., 2000; Shimuraof Drosophila dopaminergic (DA) neurons. Coexpres-
et al., 2000; Zhang et al., 2000b). Ubiquitin-protein li-sion of Parkin degrades Pael-R and suppresses its
gases are components of the ubiquitin-proteasometoxicity, whereas interfering with endogenous Dro-
pathway that degrades proteins with abnormal confor-sophila Parkin function promotes Pael-R accumula-
mations (Hershko and Ciechanover, 1998; Sherman andtion and augments its toxicity. Furthermore, overex-
Goldberg, 2001). In this pathway, ubiquitin moiety ispression of Parkin can mitigate -Synuclein-induced
transferred to substrate proteins through ubiquitin-acti-neuritic pathology and suppress its toxicity. Our study
vating enzyme (E1), ubiquitin-carrier protein (E2), andimplicates Parkin as a central player in the molecular
ubiquitin ligase (E3). After a polyubiquitin chain ispathway of Parkinson’s disease (PD) and suggests
attached to the substrate protein, it is recognized bythat manipulating Parkin expression may provide a
the 26S proteasome and targeted for degradation. Sub-novel avenue of PD therapy.
strate specificity in this reaction is largely conferred by
the interaction between E3 and the substrate.Introduction
A number of proteins have been identified as Parkin
substrates in vitro. CDCrel-1, a synaptic vesicle-associ-PD is the most common movement disorder and the
ated protein, has been shown to interact with and cansecond most common neurodegenerative diseases. PD
be ubiquitinated by Parkin (Zhang et al., 2000b). Synphi-patients suffer from rigidity, slowness of movement,
lin-1, which was originally identified as a -Syn-inter-tremor, and postural instability. The movement disorder
acting protein, has also been shown to be a substrate of
in PD is largely due to the deficiency of brain dopamine
Parkin-mediated ubiquitination and degradation (Chung
contents caused by the degeneration of DA neurons in
et al., 2001). It has not been determined whether
the midbrain. Although the mechanism underlying the CDCrel-1 or Synphilin-1 accumulates to higher levels in
selective degeneration of DA neurons is still poorly un- AR-JP patient brain as a result of loss of Parkin activity.
derstood, both exogenous environmental toxins and en- Parkin has also been shown to promote the ubiquitina-
dogenous proteotoxins have been implicated in PD tion and degradation of an O-glycosylated form of -Syn
pathogenesis (Zhang et al., 2000a; Giasson and Lee, (Sp22) (Shimura et al., 2001). The abundance of SP22
2001; Lansbury and Brice, 2002). is very low in normal brain, but it was found at modest
The molecular cloning of genes linked to familial forms levels in AR-JP brains lacking Parkin activity. It is not
of the disease has provided tremendous insights into known whether O-glycosylation is a strict prerequisite
the pathogenesis of PD. Missense mutations in the for -Syn interaction with Parkin and its subsequent
-Synuclein (-Syn) gene have been shown to be the ubiquitination and whether these modifications play any
cause of rare forms of autosomal dominant familial PD significant roles in PD pathogenesis. It is possible that
(Polymeropoulos et al., 1997; Kruger et al., 1998). -Syn through Synphilin-1, Parkin and unmodified -Syn could
is an abundant brain protein enriched at presynaptic functionally interact in the disease process.
terminals (Clayton and George, 1998). Mice with -Syn Parkin has recently been shown to ubiquitinate
gene deleted show increased striatal dopamine release Pael-R, a putative G protein-coupled transmembrane
but do not develop neurological phenotypes observed polypeptide (Imai et al., 2001). When overexpressed in
cultured cells, Pael-R tends to become unfolded and
insoluble and induces endoplasmic reticulum (ER) stress.*Correspondence: lub@mail.rockefeller.edu
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Parkin ubiquitinates Pael-R and promotes the degrada- of GAL4 is under the control of the DOPA decarboxylase
tion of the insoluble form of the protein. Moreover, the gene promoter (Li et al., 2000). Sections of aged control
insoluble form of Pael-R has been found to accumulate and transgenic fly brains were immunostained for tyro-
in AR-JP patient brains (Imai et al., 2001). However, the sine hydroxylase (TH), which specifically identifies DA
causal relationship between Pael-R accumulation and neurons. We focused our analysis on the dorsomedial
AR-JP is not clear. (DM) clusters of DA neurons, which have been well char-
To test the functional significance of Parkin’s bio- acterized and shown to preferentially degenerate in
chemical interactions with Pael-R and -Syn, we have -Syn transgenic flies (Feany and Bender, 2000; Auluck
used transgenic flies expressing human Pael-R, Parkin, et al., 2002). The DM clusters are composed of approxi-
or -Syn to analyze their in vivo relationships and their mately 18 DA neurons in wild-type adult fly brain. The
roles in the pathogenesis of PD. Panneuronal expression two clusters are distributed in a bilaterally symmetric
of Pael-R results in age-dependent selective degenera- fashion with respect to the midline (Figure 1A). The num-
tion of Drosophila DA neurons, suggesting that DA neu- ber of DA neurons in the DM clusters does not change
rons are especially susceptible to Pael-R toxicity. Coex- significantly, even in 60-day-old senescent wild-type
pression of human Parkin causes the degradation of flies. In 40-day-old transgenic flies expressing Pael-R,
Pael-R and suppresses the DA neuron degeneration however, we observed that the number of DA neurons in
phenotype, whereas interference of endogenous Dro- the DM clusters was reduced compared to the controls
sophila parkin function promotes Pael-R accumulation (Figure 1B). This reduction of DA neurons was correlated
and enhances Pael-R-induced neurotoxicity. These data with the expression level of the Pael-R transgene, as the
provide strong in vivo evidence that Pael-R is a genuine strong expression lines consistently showed a smaller
substrate for Parkin and that the accumulation of Pael-R number of DA neurons (10.8  0.5, mean  SEM) than
is a cause of DA neuron death in AR-JP. Interestingly, the moderate expression line (13.5  0.6). Expression
overexpression of Parkin can also suppress the toxicity of a control green fluorescent protein (GFP) has no effect
of -Syn, at least in part by mitigating -Syn-induced on DA neuron number (see Supplemental Figure S1 at
neuritic pathology. Our study implicates Parkin as a cen- http://www.neuron.org/cgi/content/full/37/6/911/DC1).
tral player in the pathogenesis of different forms of PD. The loss of DA neurons could be caused by late onset
neurodegeneration or early developmental abnormali-
Results ties. To distinguish these possibilities, we examined
younger flies. In newly eclosed transgenic flies (1-day-
Targeted Expression of Pael-R in Drosophila old) expressing Pael-R, the number of DA neurons in
In the sequenced Drosophila genome, there is no clear the DM clusters (18.6 0.6) was similar to that observed
fly homolog of human Pael-R. To address the role of in control flies (18.8  0.8, Figure 1C). This suggests
Pael-R in causing neurodegeneration, we used the bi- that the DA neurons are initially formed normally in the
partite UAS-GAL4 system to target the expression of transgenic flies, but over time some of these neurons
human Pael-R protein to different fly tissues and cell degenerate as a consequence of the overexpression of
types (Brand and Perrimon, 1993). This system involves Pael-R protein.
two transgenic lines, a UAS-Pael-R line, in which the
human Pael-R cDNA is placed under the control of up-
The Toxicity of Pael-R Is Relatively Selectivestream activating sequence (UAS) for the yeast tran-
toward DA Neuronsscription factor GAL4, and a GAL4 line, which expresses
We next examined the effects of expressing Pael-RGAL4 in a tissue- and cell type-specific pattern. In the
ubiquitously in all the differentiated neurons of the flyprogenies resulting from a cross between these two
nervous system using the strong UAS-Pael-R line andlines, Pael-R is expressed in the same tissue and cell
the panneuronal driver elav-GAL4 (Lin and Goodman,type where GAL4 is expressed.
1994). Western blot analysis on adult fly heads showedMultiple independent UAS-Pael-R transgenic lines
that the amount of transgene-produced Pael-R proteinwere generated through P element-mediated germline
per milligram of brain tissue in elav-GAL4 /UAS-Pael-Rtransformation. To assess the levels of Pael-R expres-
flies is 45%–55% that of endogenous Pael-R protein insion in these different transgenic lines, we crossed these
mouse brain (see Supplemental Figure S2 at http://UAS-Pael-R lines to the scabrous-GAL4 line, a strong
www.neuron.org/cgi/content/full/37/6/911/DC1). TH im-GAL4 driver line that directs transgene expression in
munostaining revealed that, similar to that observed inthe precursor cells and their differentiated progenies in
Ddc-DAL4 driven transgenic flies, the number of DAthe central and peripheral nervous system. Resulting
neurons in the DM clusters is also reduced in elav-GAL4transgenic embryos were examined for transgene ex-
driven transgenic flies (12.0  1.7; Figure 2B).pression by immunostaining with antibodies against
We then analyzed other neuronal types to see if theyPael-R. Of ten independent transgenic lines analyzed,
are also affected after panneuronal expression offour give detectable expression of the Pael-R protein as
Pael-R. The monoclonal antibody 22C10, which recog-determined by the immunostaining method. Two lines, a
nizes the Futsch antigen (Zipursky et al., 1984; Hummelstrong expression line and a moderate expression line,
et al., 2000), is highly expressed in the visual systemwere chosen for subsequent studies.
as well as the central brain complex in adult flies. The
staining of lamina and medulla neuropils by the 22C10Overexpression of Pael-R Leads to a Loss
antibody was similar between the control and Pael-Rof DA Neurons
transgenic flies (Figures 2C and 2D). Overall morphologyTo target the expression of Pael-R to DA neurons, we
used the Ddc-GAL4 driver line, in which the expression of the central brain was preserved in Pael-R transgenic
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thetic pathway of acetylcholine, showed that the
distribution and number of cholinergic neurons in major
brain cholinergic centers were similar between control
and Pael-R transgenics (data not shown). Immunostain-
ing of serotonergic neurons with anti-5HT antibody also
did not reveal any obvious reduction of these neurons
in major brain serotonergic centers (data not shown).
Although we can not exclude the possibility that a small
percentage of serotonergic or cholinergic neurons de-
generate in Pael-R transgenic flies, our analysis indi-
cates that there are no clusters of these neurons that
are vulnerable to Pael-R toxicity like the DM clusters of
DA neurons.
We also examined whether the expression of Pael-R is
toxic to cell types outside of the central nervous system
(CNS). For this purpose, we crossed the UAS-Pael-R
transgenic lines to GAL4 driver lines that have known
expression patterns in non-CNS tissues. Previous stud-
ies showed that expression of many human disease-
causing proteins such as polyglutamine repeat-con-
taining proteins, tau, and -Syn in fly eye caused defects
in eye morphogenesis and retinal degeneration (Warrick
et al., 1998; Feany and Bender, 2000; Kazemi-Esfarjani
and Benzer, 2000; Wittmann et al., 2001). In contrast,
Pael-R expression in the eye has no phenotypic conse-
quence (Figures 2E and 2F). We have targeted Pael-R
expression in the eye at different stages of eye develop-
ment using the elav-, sevenless-, gmr-, and eyeless-
GAL4 lines. In all four cases, Pael-R-expressing flies
had normal eye morphology and retina structure. Simi-
larly, no phenotype was observed when the dpp-GAL4
and 24B-GAL4 lines were used to express Pael-R along
the anterior-posterior boundary of imaginal discs and
in muscle cells, respectively.
The only phenotype outside of the nervous system
was observed when we used the apterous-GAL4 line to
direct Pael-R expression. apterous-GAL4 is expressed
in several larval imaginal discs including the dorsal mes-
othoracic and metathoracic discs. In newly eclosed flies
from a cross between the apterous-GAL4 and the strong
Pael-R lines, body fluids leaked from two spots located
in a bilaterally symmetric fashion on the dorsal thorax
at the junction between the notum and scutellum. The
fluids quickly solidified and formed two dark patches
adhering to the cuticle (Figure 3B). This phenotype isFigure 1. Age-Dependent Loss of DA Neurons in the DM Clusters
presumably caused by the degeneration of the epithelialof Pael-R Transgenic Flies
tissue or the underlying musculature at those sites.Frontal sections of aged fly brain were stained with anti-TH antibody
to identify DA neurons. The section containing most of the DA neu-
rons in the DM clusters (marked by arrows) was shown for each Coexpression of Human Parkin Suppresses
brain.
Pael-R Toxicity(A) A 40-day-old Ddc-GAL4/ control fly brain.
Given the propensity of overexpressed Pael-R to be-(B) A 40-day-old Ddc-GAL4/; UAS-Pael-R/ fly brain.
come unfolded and insoluble and elicit ER stress in(C) A 1-day-old Ddc-GAL4/; UAS-Pael-R/ fly brain.
(D) Bar graph summarizing quantitative analysis of DA neuron num- cell culture (Imai et al., 2001), it is possible that the
ber in the DM clusters in Pael-R transgenic flies and control flies. degeneration phenotype observed in Pael-R transgenic
Asterisk indicates that the difference in DA neuron number between flies is caused by the accumulation of abnormal and
40-day-old Pael-R transgenic flies and control flies is statistically
toxic forms of Pael-R protein. To test this possibility,significant (p  0.01, Student’s t test).
we asked if coexpression of human Parkin protein could
promote the degradation of these aberrant proteins and
therefore suppress Pael-R toxicity. In transgenic fliesflies, suggesting that ubiquitous expression of Pael-R
in the brain does not cause widespread degeneration. that coexpressed Pael-R and human Parkin in DA neu-
rons under the control of the Ddc-GAL4 driver, we ob-We also examined specific neuronal subtypes. Immuno-
staining with the antibody against choline acetyltrans- served that the number of DA neurons in the DM clusters
is restored to near wild-type levels (16.9  0.6; Figureferase (Yasuyama et al., 1996), an enzyme in the biosyn-
Neuron
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Figure 2. Cell Type Selectivity of Pael-R Neurotoxicity
(A–D) Frontal sections of 40-day-old elav-GAL4/ control flies (A and C) and 40-day-old elav-GAL4/; UAS-Pael-R/ flies (B and D) were
immunostained with anti-TH antibody (A and B) to identify DA neurons in the DM clusters (marked with arrows) or with 22C10 MAb (C and
D) to reveal general morphology of optic lamina (L), medulla (M), and the central brain complex (CB).
(E and F) Toluidine blue staining of elav-GAL4/ (E) or elav-GAL4/; UAS-Pael-R/ (F) adult retina to show that neither retinal architecture
nor photoreceptor neuron number is affected by Pael-R expression.
3E). Expression of the human Parkin protein alone using Human Parkin Promotes the Degradation of Pael-R
in a Neuronal Cell Type-Specific Mannerthe Ddc-GAL4 driver did not affect the number of DA
neurons in the DM clusters (Figure 3F). We wished to gain further insights into the interaction
between human Parkin and Pael-R at the molecular andWhen human Parkin and Pael-R were coexpressed
using the apterous-GAL4 driver, the thoracic toxicity of cellular level. For this purpose, we performed immuno-
histochemical analysis of human Parkin and Pael-R pro-Pael-R was also suppressed and no dark patches
formed on the dorsal thorax (Figure 3C). Coexpression of teins expressed in neural stem cell-derived DA neurons.
Isolated Drosophila embryonic neural stem cells (calledGFP did not suppress Pael-R-induced thoracic toxicity
(see Supplemental Figure S3 at http://www.neuron.org/ neuroblasts) undergo stereotyped divisions when cul-
tured in vitro. After being in culture for 12 hr, the neuro-cgi/content/full/37/6/911/DC1). Expression of human
Parkin alone using the apterous-GAL4 driver had no blast progenies exit the cell cycle and form clusters of
differentiated neuronal or glial cell types. The neuronaleffect on thoracic morphology (Figure 3D). These results
indicate that coexpression of human Parkin suppressed progenies, which include an appropriate proportion of
TH-positive DA neurons (Figures 4G and 4H), are stablePael-R toxicity in two different cell types.
Role of Parkin and Its Substrates in PD
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Figure 3. Suppression of Pael-R Toxicity by the Coexpression of Parkin
(A and B) Expression of Pael-R using the apterous-GAL4 driver leads to degeneration of the notum, as indicated by the leakage of body fluids
(marked by arrows in B), which is absent in control flies (A).
(C–F) Coexpression of a transgene expressing human Parkin completely suppressed this thoracic degeneration phenotype (C). Note that the
scutellum bristles are pointing upwards and out of focus in this image. Coexpression of human Parkin also completely suppressed the loss
of DA neurons in the DM clusters (marked by arrows in E). Expression of human Parkin alone has no effect on either thoracic morphology
(D) or DA neuron number in the DM clusters (F). The genotypes are apterous-GAL4/ (A), apterous-GAL4/; UAS-Pael-R/ (B), apterous-
GAL4/UAS-hParkin; UAS-Pael-R/ (C), apterous-GAL4/UAS-hParkin (D), Ddc-GAL4/; UAS-hParkin/UAS-Pael-R (E), and Ddc-GAL4/; UAS-
hParkin/ (F).
(G) Bar graph summarizing quantitative analysis of DA neuron number in the DM clusters in 40-day-old Pael-R transgenic flies with and without
Parkin coexpression. Asterisk indicates that the difference in DA neuron numbers between the two conditions is statistically significant (p 
0.01, Student’s t test).
in culture for weeks. In cultured DA neurons, Pael-R is of Pael-R protein as judged by immunostaining (Figures
5C and 5D). Interestingly, there was a significant portionmainly localized to the cell surface, as indicated by its
colocalization with Numb, a membrane protein (Figures (63/235) of neurons that still expressed normal levels of
Pael-R protein in the presence of Parkin (Figure 5D).4A–4C). There is also a lower level of expression in neu-
ronal processes. Human Parkin protein exhibits similar Because the action of Parkin requires E1, E2, and possi-
bly other cofactors, these neurons may miss certainlocalization pattern in cultured DA neurons, but its local-
ization to neuronal processes is more pronounced and cofactors required for Parkin-mediated degradation of
Pael-R.appears punctate. Double labeling with Synaptotagmin
suggests that the punctate staining of Parkin in neuronal We then tested whether DA neurons have the capacity
to degrade Pael-R in the presence of human Parkin. Weprocesses represents its association with synaptic vesi-
cles (Figures 4D–4F). This is consistent with earlier find- coexpressed these two proteins in cultured DA neurons
using the Ddc-GAL4 driver. Similar to that observed inings in mammalian cell culture (Kubo et al., 2001).
We next examined the interaction between Pael-R elav-GAL4 neuronal culture described above, in younger
cultures (1–2 days old) Pael-R and Parkin showed colo-and human Parkin when they were coexpressed in post-
mitotic neurons under the control of the elav-GAL4 calization, and in most Ddc-GAL4-expressing neurons
(27/31), the level of Pael-R was similar to that observeddriver. In 1- or 2-day-old neuronal culture, Pael-R and
Parkin showed colocalization, and in most neurons (135/ in neurons expressing Pael-R alone (Figures 5E and 5F).
But in older neuronal culture (4–6 days), Pael-R protein154) the level of Pael-R protein was similar to that ob-
served in neurons expressing Pael-R alone (Figures 5A level was markedly reduced in most Ddc-GAL4-express-
ing neurons (21/29; Figure 5H). In contrast, control neu-and 5B). In 6-day-old culture, however, the majority of
these neurons (172/235) showed a significant reduction rons expressing Pael-R in the absence of Parkin showed
Neuron
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Figure 4. Subcellular Localization of Pael-R and Parkin in Cultured Neurons
(A–C) Membrane localization of Pael-R. A neuronal cluster generated from an elav-GAL4/; UAS-Pael-R/ genotyped neuroblast was double-
labeled for Pael-R (B) and Numb (A), a membrane protein. The merged image in (C) shows colocalization of Pael-R and Numb at the plasma
membrane. Pael-R also shows lower level of expression in neuronal processes, which are out of focus in this image.
(D–F) Vesicular localization of Parkin. A neuronal cluster generated from an elav-GAL4/; UAS-hParkin/ genotyped neuroblast was double
labeled for Parkin (E) and Synaptotagmin (D), a synaptic vesicle protein. The merged image in (F) shows colocalization of Parkin and
Synaptotagmin in vesicular structures of neuronal processes.
(G and H) Generation of DA neurons from cultured neuroblasts. A neuronal cluster generated from a Ddc-GAL4/; UAS-GFP/ genotyped
neuroblast was immunostained for TH (H). One of the two GFP-expressing neurons (marked by an arrow in H) is TH positive and thus
dopaminergic; the other one is likely a serotonergic neuron, which also expresses Ddc-GAL4.
robust Pael-R expression in 6-day-old culture (Figure fly brain demonstrate that Parkin promotes the degrada-
tion of Pael-R under physiological conditions.5J). Thus, we conclude that human Parkin promotes the
degradation of Pael-R in selective groups of Drosophila
neurons including DA neurons. RNA Interference of the Fly Homolog of Parkin
To demonstrate the in vivo relevance of our results Promotes Pael-R Accumulation and
showing Parkin-mediated degradation of Pael-R in cell Accelerates Pael-R-Induced Neurodegeneration
culture experiments, we used Western blot analysis to Our initial observation that in more than half of the Pael-R
quantify Pael-R protein levels in transgenic flies with or transgenic lines the protein is present at a low level
without Parkin coexpression. Due to the small number undetectable by immunostaining suggests that there are
of neurons expressing Ddc-GAL4 and the sensitivity of mechanisms in Drosophila that limit its accumulation.
available Pael-R antibodies, we were unable to detect Recent sequencing of the Drosophila genome has re-
Pael-R protein in Ddc-Gal4 driven transgenic flies, even vealed a fly homolog of human Parkin, dParkin (Rubin
in the absence of Parkin. Therefore, we used elav-GAL4 et al., 2000). To test whether dParkin genetically inter-
driven transgenic flies, which express Pael-R protein in acts with the Pael-R transgene, we used the RNA inter-
more cells. In head extracts obtained from 30-day-old ference (RNAi) technique (Fire et al., 1998) to inhibit
Pael-R transgenic flies driven by elav-GAL4, we ob- dParkin expression and examined the effect on Pael-R-
served a significant reduction of Pael-R protein level induced DA neuron degeneration. To inhibit the expres-
in the presence of coexpressed Parkin (Figure 5K). In sion of dParkin in DA neurons of adult fly brain, we
contrast, coexpression of Parkin has little effect on the generated UAS-IRdParkin transgenic flies that express
level of a control GFP protein (see Supplemental Figure double-stranded dParkin RNA as hairpin RNA from an
S4 at http://www.neuron.org/cgi/content/full/37/6/ inverted repeat of dParkin cDNA (Kennerdell and Car-
911/DC1). Together, our immunohistochemical analysis thew, 2000). Ubiquitous expression of hairpin dParkin
RNA using a heat shock-GAL4 driver line resulted in aon cultured neurons and Western blot analysis on adult
Role of Parkin and Its Substrates in PD
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Figure 5. Parkin Promotes the Degradation
of Pael-R
(A–D) Double labeling of neuronal clusters de-
rived from elav-GAL4/; UAS-Pael-R/UAS-
hParkin genotyped neuroblasts using anti-
Parkin (A and C) and anti-Pael-R (B and D)
antibodies. The neuronal culture shown in (A)
and (B) is 2 days old and the one in (C) and
(D) is 6 days old.
(E–H) Double labeling of DA neurons derived
from Ddc-GAL4/; UAS-Pael-R/UAS-hPar-
kin genotyped neuroblasts using anti-Parkin
(E and G) and anti-Pael-R (F and H) antibod-
ies. The neuronal culture shown in (E) and (F)
is 2 days old and the one in (G) and (H) is 6
days old. Note that in 6-day-old culture many
of the Parkin-coexpressing neurons have di-
minished Pael-R protein expression. Diluted
anti-Pael-R antibody (1:10,000) was used to
detect the difference in Pael-R protein level.
(I and J) Double labeling of DA neurons de-
rived from Ddc-GAL4/; UAS-Pael-R/ ge-
notyped neuroblasts using anti-Parkin (I) and
anti-Pael-R (J) antibodies to show that in the
absence of Parkin, Pael-R is robustly ex-
pressed in 6-day-old DA neurons.
(K) Western blot analysis showing that Pael-
R protein level is greatly reduced in adult flies
coexpressing Parkin. Head extracts made
from 30-day-old elav-GAL4 control flies
(elav), elav-GAL4/; UAS-Pael-R/ (elav
Pael-R), and elav-GAL4/; UAS-Pael-R/
UAS-hParkin (elav Pael-R Parkin) transgenic
flies were probed with anti-Pael-R and then
reprobed with anti-Actin.
significant reduction of endogenous dParkin mRNA as copies of IRdParkin showed more severe DA degenera-
tion phenotypes when analyzed at 30 days of age, withdetermined by quantitative RT-PCR analysis (Figure 6E).
When IRdParkin and Pael-R transgenes were coex- the average number of DA neurons in the DM clusters
reduced by more than 50% to 7.8 0.5 (Figures 6D andpressed in transgenic flies using the Ddc-GAL4 driver,
we observed a dosage-dependent acceleration of Pael- 6F). Thus, inhibition of endogenous dParkin function
accelerated the kinetics and enhanced the severity ofR-induced DA neuron degeneration. Transgenic flies
coexpressing Pael-R and two copies of the IRdParkin Pael-R-induced degeneration of DA neurons. In trans-
genic flies that expressed IRdParkin alone, the numbertransgene showed the degeneration phenotype when
they were analyzed at 14 days of age (Figure 6B). At of DA neurons in the DM clusters was not significantly
affected in 30-day-old flies (17.8  1.0; Figure 6F). Thisthis age, transgenic flies expressing Pael-R alone or
coexpressing Pael-R and one copy of the IRdParkin indicates that activation of the RNAi pathway by itself
is not deleterious to DA neurons. The lack of DA neuronaltransgene showed a relatively normal number of DA
neurons in the DM clusters (Figures 6A and 6F). Further- loss by dParkin RNAi alone may be due to the absence
of toxic substrates such as Pael-R in Drosophila or thatmore, transgenic flies coexpressing Pael-R and two
Neuron
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Figure 6. Interference of dParkin Function by RNAi Enhances Pael-R Toxicity
(A–D) Frontal sections showing TH immunostaining of DA neurons in the DM clusters of Ddc-GAL4/; UAS-Pael-R/ (A and C) and Ddc-
GAL4, UAS-IRdParkin/UAS-IRdParkin, UAS-Pael-R (B and D) genotyped flies that are 14 days (A and B) or 30 days (C and D) old.
(E) RT-PCR analysis showing a reduction of endogenous dParkin mRNA level after transgenic RNAi. Second instar hs-GAL4/UAS-IRdParkin
larvae with (lanes 2 and 4) or without (lanes 1 and 3) heat shock treatment were used to prepare total RNAs for the RT-PCR analysis. PCR
primers located outside of the inverted repeat region were used to amplify endogenous dParkin, and an rp49 primer pair was used as an
internal control. Samples in lanes 1 and 2 and lanes 3 and 4 are derived from two independent experiments.
(F) Bar graph showing quantitative analysis of DA neuron number in the DM clusters of 30-day-old Pael-R transgenic flies with one or two
copies of IRdParkin transgene coexpression. Asterisks indicate that the differences in DA neuron numbers between the compared genotypes
are statistically significant (p  0.01, Student’s t test).
endogenous dParkin substrates may never accumulate subcellular distribution of Pael-R protein. To investigate
the mechanisms involved, we analyzed Pael-R proteinto levels sufficient to kill DA neurons. However, since
RNAi in our IRdParkin transgenic flies results in a reduc- by immunostaining cultured DA neurons that coex-
pressed IRdParkin and Pael-R. As shown in Figures 7Ction but not complete loss of dParkin transcripts, it is
possible that the residual dParkin may still provide neu- and 7D, coexpression of IRdParkin and Pael-R in DA
neurons results in the accumulation of Pael-R to higherroprotective function. Generation of genetic null muta-
tions in the dParkin locus could address this issue. levels compared to expression of Pael-R alone (Figures
7A and 7B). Some of the accumulated Pael-R proteinThe acceleration of DA neuron degeneration after
dParkin RNAi could be due to defects in the turnover or was unevenly distributed (Figure 7D). Thus, interfering
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Figure 7. Interference of dParkin Function
Promotes the Accumulation of Pael-R
DA neurons derived from Ddc-GAL4, UAS-
Pael-R/ (A and B) or Ddc-GAL4, UAS-
IRdParkin/ UAS-IRdParkin, UAS-Pael-R (C
and D) genotyped neuroblasts were cultured
for 6 days and then immunostained with anti-
Pael-R antibody. (B) and (D) are higher-mag-
nification views of the neurons shown in (A)
and (C). Arrows in (D) mark the uneven accu-
mulation of Pael-R protein at the periphery of
cell membrane.
with endogenous dParkin function results in increased is not known whether all of these grain-like structures
represent pathological forms of -Syn, the suppressionstability and accumulation of Pael-R protein. This may
be responsible for the acceleration and enhancement of -Syn toxicity and concomitant reduction of these
structures by Parkin coexpression suggest that at leastof Pael-R-induced DA neuron degeneration observed in
dParkin RNAi transgenic flies. some of them correspond to toxic forms of -Syn. To
further characterize the effect of Parkin overexpression
on neuritic pathology induced by -Syn, we stainedOverexpression of Parkin Suppresses
-Syn transgenic fly brain with ubiquitin antibody, which-Syn Toxicity
can recognize Lewy bodies and Lewy neurites in humanBiochemical interactions between Parkin and Pael-R or
PD patient brain. In Ddc-GAL4 driven -Syn transgenican O-glycosylated form of -Syn suggest that Parkin
fly brain, numerous ubiquitin-positive neurites could bemay be a common player in the proteasome pathway
detected. In Parkin-coexpressing flies, however, suchthat regulates the metabolism of these two proteins.
abnormal neurites were almost completely eliminatedThe detection of Parkin in Lewy bodies of Parkinson’s
(Figures 8H and 8I). Therefore, mitigation of -Syn toxic-disease and dementia with Lewy bodies (Shimura et al.,
ity by Parkin overexppression is associated with re-2001; Schlossmacher et al., 2002) further suggests that
duced -Syn-induced neuritic pathology and reducedeither Parkin is actively engaged in degrading abnormal
aggregation of -Syn.-Syn proteins or that Parkin is sequestered by -Syn
into inactive complexes in the aggregates. In either case,
overexpression of Parkin would be predicted to enhance Discussion
the degradation of abnormal -Syn or to compensate
for the reduction of Parkin activity caused by -Syn The underlying molecules and cellular pathways that
mediate neuronal death in most human neurodegenera-sequestration and therefore suppress -Syn toxicity. To
test this hypothesis, we coexpressed -Syn together tive diseases remain poorly defined. Modeling of these
diseases in experimental organisms offers the powerwith human Parkin in DA neurons. While the expression
of wild-type or pathological forms of -Syn (A30P or of genetic analysis to help understand the pathogenic
processes. By expressing the human Parkin substrateA53T) consistently caused a 50% reduction of DA neu-
rons in the DM clusters in 20-day-old flies (Figure 8A), protein Pael-R in Drosophila, we have developed a fly
model of DA neuron degeneration in AR-JP. In additionthis loss of DA neurons was suppressed when Parkin
was coexpressed with -Syn (Figure 8B). Interestingly, to providing the first in vivo evidence that accumulation
of Pael-R causes neurotoxicity and may contribute tounlike Parkin suppression of Pael-R toxicity, which is
accompanied by a dramatic reduction of overall Pael-R DA neuronal death in AR-JP, our study has provided
the following new insights into the mechanisms of neu-protein level, immunohistochemical analysis showed
that -Syn level is comparable in transgenic flies with rodegeneration in PD. First, our panneuronal and tar-
geted expression studies showed that DA neurons areor without Parkin coexpression (Figures 8C and 8D).
This is further confirmed by Western blot analysis (Figure particularly susceptible to Pael-R toxicity, thus provid-
ing new clues on cell type specificity of neurodegenera-8E). Detailed examination of -Syn distribution in DA
neurons in the DM clusters revealed that while -Syn tion in PD. Second, the effect of Parkin overexpression
on -Syn-induced neuritic pathology indicates that theformed numerous grain-like structures in the processes,
there was a marked reduction of such structures in Par- main site of action for both proteins is in neuronal pro-
cesses. Third, the suppression of neurotoxicity inducedkin-coexpressing flies (Figures 8F and 8G). Although it
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Figure 8. Suppression of -Syn Toxicity by the Coexpression of Parkin
(A and B) TH immunostaining of frontal sections of 20-day-old fly brain expressing -Syn alone (A) or coexpressing -Syn and Parkin (B)
under the Ddc-GAL4 driver control. Arrows mark the DM clusters of DA neurons.
(C and D) Immunostaining of total -Syn protein in 20-day-old Ddc-GAL4/; UAS--Syn / (C) or Ddc-GAL4/; UAS--Syn /UAS-hParkin (D)
transgenic fly brain.
(E) Western blot analysis showing that Parkin coexpression does not cause a significant change in total -Syn protein level. Head extracts
made from 20-day-old elav-GAL4 control flies (elav), or elav-GAL4/; UAS--Syn / (elav Syn), and elav-GAL4/; UAS--Syn /UAS-hParkin
(elav Syn Parkin) transgenic flies were probed with anti--Syn antibody (LB509) and then reprobed with anti-Actin as loading control.
(F and G) Immunostaining of grain-like structures in dopaminergic neurites in the area of the DM clusters in 10-day-old Ddc-GAL4/; UAS-
-Syn / (F) or Ddc-GAL4/; UAS--Syn /UAS-hParkin (G) transgenic flies.
(H and I) Anti-ubiquitin staining of 10-day-old Ddc-GAL4/; UAS--Syn / (H) or Ddc-GAL4/; UAS--Syn /UAS-hParkin (I) transgenic flies.
Arrows in (H) mark ubiquitin-positive neurites.
(J and K) Bar graphs showing quantitative analysis of DA neuron number in the DM clusters in 20-day-old -Syn transgenic flies with or
without Parkin coexpression (J) or the number of -Syn-positive grain-like neuritic structures (K) in 10-day-old -Syn transgenic flies with or
without Parkin coexpression. Asterisks indicate the differences in DA neuron number or the number of grain-like structure between the
compared genotypes are statistically significant (p  0.01, Student’s t test).
by two different proteins by Parkin suggests that Parkin interfere with Parkin’s normal function in the ubiquitin/
proteasome pathway and contribute to -Syn toxicity.may play a central role in the pathobiology of different
forms of PD. The latter scenario is consistent with our observation of
accumulated ubiquitin immunostaining in -Syn trans-
genic neurites and its disappearance after Parkin over-A General Role for Parkin in Cellular Quality
Control and Its Therapeutic Potential expression. A recent report showed that overexpression
of mutant -Syn protein increases the sensitivity to pro-The ability of overexpressed Parkin to suppress both
Pael-R and -Syn toxicity suggests that despite the dif- teasome inhibitors by decreasing proteasome function
in mammalian cell culture, an effect that can be sup-ference in pathological manifestation between the re-
cessive and dominant forms of PD, there is a common pressed by overexpression of Parkin (Petrucelli et al.,
2002). This is also consistent with the latter possibility.pathway of PD pathogenesis in which Parkin is a central
player. The observation that Parkin is localized to Lewy However, our observation of reduced neuritic -Syn ag-
gregates in Parkin-coexpressing flies is also consistentbodies is consistent with this notion (Shimura et al.,
2001; Schlossmacher et al., 2002). It is possible that with the former possibility that Parkin directly acts on
abnormal forms of -Syn, which may constitute only aParkin is actively engaged in degrading abnormal -Syn
proteins in Lewy bodies. It is also possible that Parkin minor portion of total -Syn protein in the cell. It is likely
that both mechanisms may be involved in the diseasemay be sequestered by -Syn into inactive complexes,
similar to the sequestration of transcription factor CBP process.
Previous studies have shown that in response to un-by polyglutamine-repeat proteins into nuclear inclusions
in Huntington’s disease (Nucifora et al., 2001). This may folded protein response (UPR), Parkin becomes upregu-
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lated at both the mRNA and protein level and that over- mainly in the ER. The Hsp70 class of molecular chaper-
ones may have limited access to misfolded Pael-R orexpression of Parkin can suppress UPR-induced cell
death in cell culture models (Imai et al., 2000). Thus, have limited ability to renature misfolded Pael-R pro-
teins, and therefore the Parkin-mediated proteosomeParkin may play a more general role in cellular quality
control to protect neurons from unfolded protein-induced pathway may play a more dominant role in clearing them.
Alternatively, other molecular chaperones may playstress. It is therefore conceivable that overexpression
of Parkin could also suppress neurotoxicity induced by more prominent roles in regulating the fate of misfolded
Pael-R. One good candidate is the ER resident molecu-unfolded proteins other than Pael-R and -Syn. Given
that overexpression of Parkin does not have obvious lar chaperone BiP (GRP78), which associates with un-
folded proteins in the ER and has been shown to bedetrimental effects on the animal, manipulation of Parkin
expression with small molecules may provide an effec- upregulated during ER stress and in AR-JP patient brain
(Imai et al., 2000, 2001).tive strategy for PD therapy.
Contributions by the Ubiquitin-Proteasome Pathway On the Selectivity of DA Neuronal Death in AR-JP
One of the most intriguing features of neurodegenerativeand Molecular Chaperones in Removing Misfolded
Proteins in Neurodegenerative Diseases diseases is the cell type specificity of neuronal death.
Previous studies suggested that the restricted tissueOur current and previous studies place AR-JP into the
group of neurodegenerative disorders characterized by distribution of Pael-R might contribute to the selective
degeneration of DA neurons in AR-JP (Imai et al., 2001).the accumulation and aggregation of aberrant forms of
proteins. This includes Amyotrophic Lateral Sclerosis, It was shown that Pael-R protein is widely expressed in
the mouse brain, predominantly in oligodendrocytes. ItsAlzheimer’s disease, Huntington’s disease, the late on-
set dominantly inherited forms of PD, and spongiform neuronal expression is restricted to a subset of neurons
such as DA neurons in the substantia nigra and hippo-encephalopathies (Sherman and Goldberg, 2001). In
these various forms of neurodegenerative diseases, campal neurons in the CA3 region. While the restricted
tissue distribution of Pael-R may partially explain thespecific groups of neurons undergo degeneration as a
result of the aggregation of distinct misfolded proteins. selectivity of neuronal degeneration in AR-JP, this study
shows that there are some features specific to the DAThese proteins may cause cellular toxicity by affecting
different aspects of neuronal physiology, from axonal neurons that contribute to their particular vulnerability
to Pael-R toxicity. It is possible that this selective vulner-transport (Gunawardena and Goldstein, 2001) and syn-
aptogenesis (Walsh et al., 2002) to gene expression in ability is due to a smaller capacity of DA neurons to
handle Pael-R-induced ER stress. It is also possible thatthe nucleus (Nucifora et al., 2001). In the case of Pael-R,
abnormal forms of the protein may cause cellular toxicity certain DA neuron-specific cofactors may contribute to
Pael-R toxicity. Two risk factors, oxidative stress andthrough eliciting ER stress (Imai et al., 2001). Compo-
nents of the ubiquitin-proteasome degradation pathway dopamine, have been suggested to contribute to the
selective toxicity of -Syn toward DA neurons. DA neu-and molecular chaperones have been shown to associ-
ate with inclusions formed by these different proteins rons in the substantia nigra are known to produce ex-
cess reactive oxygen species such as superoxide anion,(Sherman and Goldberg, 2001). This may reflect the
cell’s strategy to eliminate these misfolded proteins by which in reaction with nitric oxide (NO) can generate the
more potent oxidant peroxynitrite and cause damagesrepairing/refolding them with the molecular chaperones
or degrading them through the ubiquitin-proteasome to proteins and other macromolecules (Giasson et al.,
2000). It was also shown that dopamine can be ligatedsystem.
The importance of the ubiquitin-proteasome system to -Syn to form dopamine--Syn adducts (Conway et
al., 2001). This adduct selectively inhibits the protofibril-in neurodegeneration is highlighted by the association
of familial forms of PD with mutations in Parkin and to-fibril conversion and causes the accumulation of
-Syn protofibrils, which are the presumed toxic spe-ubiquitin carboxy-terminal hydrolase L1 (UCHL-1), an-
other enzyme involved in ubiquitin metabolism (Leroy cies. Future studies will test whether Pael-R is also modi-
fied by oxidative stress and dopamine and whetheret al., 1998), and the acceleration of SCA1 phenotype
by loss-of-function of an E3 ubiquitin ligase in mice these modifications contribute to its toxicity.
Many studies have shown that there is unanticipated(Cummings et al., 1999). Hsp70 molecular chaperones
have been implicated in disease processes by whole ani- conservation of signaling pathways, regulatory mecha-
nisms, and cellular and physiological processes be-mal studies in Drosophila, which showed that directed
overexpression of Hsp70 attenuates whereas interfer- tween flies and humans. Our identification of Parkin as
an important modulator of Pael-R and -Syn toxicityence with endogenous chaperone activity exacerbates
neurotoxicity associated with polyglutamine repeat-con- suggests that we could use the fly models to further
understand the role of Parkin and its substrates in thetaining proteins and -Syn (Warrick et al., 1999; Auluck et
al., 2002). It remains to be determined whether Hsp70 pathogenesis of PD. The ability to perform facile genetic
loss-of-function and overexpression screens in this sys-molecular chaperones play significant roles in removing
misfolded Pael-R protein. The fate of abnormal Pael-R tem will allow us to identify new genes that can either
attenuate or exacerbate disease phenotypes. Suchprotein depends on the relative kinetics of its interac-
tions with the molecular chaperone pathway and the studies will allow us to delineate the molecular pathways
involved in the pathogenesis of PD and possibly otherproteasome pathway (Imai et al., 2002). Unlike -Syn, a
small cytosolic protein, Pael-R is a large 7 transmem- related neurodegenerative diseases and identify poten-
tial therapeutic drug targets.brane protein, the misfolded forms of which reside
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Experimental Procedures blue was performed as described (Wolff, 2000). Between five and
ten fly heads for each genotype per time point were examined and
each experiment was repeated at least once.Fly Stocks
All general fly stocks and GAL4 lines were obtained from the
Bloomington Drosophila stock center. Flies were grown under stan- Western Blot Analysis
dard conditions at 25C. The w strain was used to generate trans- To analyze Pael-R and -Syn protein levels with or without Parkin
genic flies. The UAS-hsp70 and the UAS--Syn lines were provided coexpression, UAS-Pael-R or UAS--Syn transgenic male flies were
by Dr. Nancy Bonini (Warrick et al., 1998; Auluck et al., 2002). The first crossed to elav-Gal4 females. F1 male progenies were crossed
Ddc-GAL4 line was provided by Dr. Jay Hirsh (Li et al., 2000). to w or UAS-hParkin transgenic females. Female flies resulting
from above crosses were used to make head extracts for Western
blot analysis. Half of these females express Pael-R or -Syn pro-Constructs and Transgenics
teins. Typically extracts made from five to ten fly heads were sepa-To construct UAS-hParkin and UAS-Pael-R plasmids, the full-length
rated by SDS-PAGE and probed with mouse anti-Pael-R (1:1000) orcDNAs were released from pcDNA3.1-hParkin and pcDNA3.1-
LB509 anti-Synuclein (1:500). Antibody detection was done usingPael-R plasmids with EcoRI/XbaI and EcoRI/XhoI double digests,
the Amersham ECL system. To control for equal loading, the blotsrespectively (Imai et al., 2001). The inserts were subsequently cloned
were stripped and reprobed with mouse anti-Actin (1:5000). In con-into corresponding double digested pUAST vectors.
trol experiments, we demonstrated that added expression of a con-The Drosophila parkin homolog dParkin was amplified from a third
trol UAS-GFP transgene has no effect on the level of expression ofinstar larval cDNA library by polymerase chain reaction (PCR). The
Pael-R or -Syn (see Supplemental Figure S5 at http://www.neuron.Advantage HF-2 PCR kit (Clontech) was used for PCR. The PCR
org/cgi/content/full/37/6/911/DC1).product was cloned into pCR2.1-TOPO vector using the TOPO
PCR Cloning Kit (Invitrogen). Two plasmids in which the dParkin
AcknowledgmentsPCR product was inserted in opposite orientations were chosen
for constructing inverted repeats of dParkin (IRdParkin). Detailed
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